Yang Yang,Lilin He. Immunotherapy induced hypothyroidism with hyperlipidemia: a case report and literature review. Oncol Transl Med, 2022, 8: 100-103.
Immunotherapy induced hypothyroidism with hyperlipidemia: a case report and literature review
Received:March 29, 2022  Revised:April 29, 2022
View Full Text  View/Add Comment  Download reader
KeyWord:immune-related adverse effects (irAEs); hyperlipidemia; hypothyroidism; immune checkpoint; inhibitors (ICIs); sintilimab; immunotherapy
Author NameAffiliationE-mail
Yang Yang First People''''s Hospital of Tianmen,Hubei Tianmen , People’s Republic of China 867900913@qq.com 
Lilin He First People''''s Hospital of Tianmen,Hubei Tianmen , People’s Republic of China 372135535@qq.com 
Hits: 2225
Download times: 2629
Abstract:
      In recent years, immune checkpoint inhibitors have been increasingly used in clinical practice. While considering the efficacy of immunotherapy, it is also necessary to be alert to immune-related adverse effects (irAEs). These include skin, gastrointestinal, liver, endocrine, and pulmonary toxicities. Here, we report a case of irAEs of hypothyroidism with marked hyperlipidemia during sintilimab administration.
Close